Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Feb;18(2):113-117.
doi: 10.1080/14737159.2018.1410060. Epub 2017 Dec 1.

What is the potential of nanolock- and nanocross-nanopore technology in cancer diagnosis?

Li-Qun Gu  1 , Kent S Gates  2 , Michael X Wang  3 , Guangfu Li  4
Affiliations
Review

What is the potential of nanolock- and nanocross-nanopore technology in cancer diagnosis?

Li-Qun Gu et al. Expert Rev Mol Diagn. 2018 Feb.
No abstract available

Keywords: Cancer diagnostics; Point-of-care; Precision medicine; biosensor; driver mutation; nanocross; nanolock; nanopore; precision oncology; single nucleotide polymorphism (SNP).

PubMed Disclaimer

Conflict of interest statement

Declaration of Interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Figures

Figure 1.
Figure 1.
Single-molecule detection of cancer driver mutation by using nanolock-nanapore and nanocross-nanopore sensors. a. Nanolock-nanopore detection of the BRAF V600E mutant allele in tumor tissue DNA sample; b. Nanocross-nanopore detection of the BRAF V600E mutant DNA sequence. In both methods, the non-covalent nanolock (a) or covalent nanocros is constructed only on the mutant-probe DNA complex. Their special molecular configuration changes in the nanopore produce a unique ion current signature (current blockade marked by red solid triangle), which serves as a fingerprint of a single mutant DNA molecule. For the nanocross method (b), the unique long-duration blockade by the nanocross enables multi-nanopore simultaneous detection of mutant DNA; c. Identification of mutant fingerprints enables Yes/No early cancer diagnostics, and counting of mutant fingerprints allows quantitation of mutant frequency for personalized treatment. This figure was adapted with permission from (Wang Y, Tian K, Shi R et al. Nanolock-Nanopore Facilitated Digital Diagnostics of Cancer Driver Mutation in Tumor Tissue. ACS sensors, 2(7), 975–981 (2017)). Copyright (2017) American Chemical Society; adapted with permission from (Zhang X, Price NE, Fang X, Yang Z, Gu LQ, Gates KS. Characterization of Interstrand DNA-DNA Cross-Links Using the alpha-Hemolysin Protein Nanopore. ACS nano, 9(12), 11812–11819 (2015)). Copyright (2015) American Chemical Society; adapted from (Nejad MI, Shi R, Zhang X, Gu LQ, Gates KS. Sequence- Specific Covalent Capture Coupled with High-Contrast Nanopore Detection of a Disease- Derived Nucleic Acid Sequence. ChemBioChem, 18(14), 1383–1386 (2017)) with permission of John Wiley and Sons, Copyright (2017).
See this image and copyright information in PMC

References

    1. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr., Kinzler KW. Cancer genome landscapes. Science, 339(6127), 1546–1558 (2013). - PMC - PubMed
    1. Lee JS. Exploring cancer genomic data from the cancer genome atlas project. BMB reports, 49(11), 607–611 (2016). - PMC - PubMed
    1. Couch FJ, Nathanson KL, Offit K. Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science, 343(6178), 1466–1470 (2014). - PMC - PubMed
    1. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. The New England journal of medicine, 350(21), 2129–2139 (2004). - PubMed
    1. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304(5676), 1497–1500 (2004). - PubMed

LinkOut - more resources